img

Global Neuromuscular Blockade Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neuromuscular Blockade Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Neuromuscular blocking agents or medications are the type of muscle relaxants that are widely used to prevent muscle contraction during surgery. They are structurally similar to acetylcholine and bring muscle relaxation by post-synaptic binding to acetylcholine receptors. Furthermore, when artificial ventilation is available, such agents should be used instead of anesthesia.
Neuromuscular Blockade Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Neuromuscular Blockade Drugs market is projected to reach US$ 6729.1 million in 2029, increasing from US$ 5012 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neuromuscular Blockade Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


F. Hoffmann-La Roche Ltd
Mylan N.V
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK plc
Novartis AG
AstraZeneca
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd
Merck & Co., Inc
Lilly
Amgen Inc
Actelion Pharmaceuticals Ltd
Endo International plc
Intas Pharmaceuticals Ltd
Segment by Type
Depolarizing
Non-Depolarizing

Segment by Application


Hospitals
Specialty Clinics
Other

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Neuromuscular Blockade Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Neuromuscular Blockade Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Neuromuscular Blockade Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Neuromuscular Blockade Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Neuromuscular Blockade Drugs introduction, etc. Neuromuscular Blockade Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Neuromuscular Blockade Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Neuromuscular Blockade Drugs Market Overview
1.1 Neuromuscular Blockade Drugs Product Overview
1.2 Neuromuscular Blockade Drugs Market Segment by Type
1.2.1 Depolarizing
1.2.2 Non-Depolarizing
1.3 Global Neuromuscular Blockade Drugs Market Size by Type
1.3.1 Global Neuromuscular Blockade Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Neuromuscular Blockade Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Neuromuscular Blockade Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Neuromuscular Blockade Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Neuromuscular Blockade Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Neuromuscular Blockade Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Neuromuscular Blockade Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Neuromuscular Blockade Drugs Sales Breakdown by Type (2018-2024)
2 Global Neuromuscular Blockade Drugs Market Competition by Company
2.1 Global Top Players by Neuromuscular Blockade Drugs Sales (2018-2024)
2.2 Global Top Players by Neuromuscular Blockade Drugs Revenue (2018-2024)
2.3 Global Top Players by Neuromuscular Blockade Drugs Price (2018-2024)
2.4 Global Top Manufacturers Neuromuscular Blockade Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Neuromuscular Blockade Drugs Market Competitive Situation and Trends
2.5.1 Neuromuscular Blockade Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Neuromuscular Blockade Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuromuscular Blockade Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Neuromuscular Blockade Drugs Market
2.8 Key Manufacturers Neuromuscular Blockade Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Neuromuscular Blockade Drugs Status and Outlook by Region
3.1 Global Neuromuscular Blockade Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Neuromuscular Blockade Drugs Historic Market Size by Region
3.2.1 Global Neuromuscular Blockade Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Neuromuscular Blockade Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Neuromuscular Blockade Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Neuromuscular Blockade Drugs Forecasted Market Size by Region
3.3.1 Global Neuromuscular Blockade Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Neuromuscular Blockade Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Neuromuscular Blockade Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Neuromuscular Blockade Drugs by Application
4.1 Neuromuscular Blockade Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Other
4.2 Global Neuromuscular Blockade Drugs Market Size by Application
4.2.1 Global Neuromuscular Blockade Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Neuromuscular Blockade Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Neuromuscular Blockade Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Neuromuscular Blockade Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Neuromuscular Blockade Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Neuromuscular Blockade Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Neuromuscular Blockade Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Neuromuscular Blockade Drugs Sales Breakdown by Application (2018-2024)
5 North America Neuromuscular Blockade Drugs by Country
5.1 North America Neuromuscular Blockade Drugs Historic Market Size by Country
5.1.1 North America Neuromuscular Blockade Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Neuromuscular Blockade Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Neuromuscular Blockade Drugs Sales in Value by Country (2018-2024)
5.2 North America Neuromuscular Blockade Drugs Forecasted Market Size by Country
5.2.1 North America Neuromuscular Blockade Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Neuromuscular Blockade Drugs Sales in Value by Country (2024-2029)
6 Europe Neuromuscular Blockade Drugs by Country
6.1 Europe Neuromuscular Blockade Drugs Historic Market Size by Country
6.1.1 Europe Neuromuscular Blockade Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Neuromuscular Blockade Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Neuromuscular Blockade Drugs Sales in Value by Country (2018-2024)
6.2 Europe Neuromuscular Blockade Drugs Forecasted Market Size by Country
6.2.1 Europe Neuromuscular Blockade Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Neuromuscular Blockade Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Neuromuscular Blockade Drugs by Region
7.1 Asia-Pacific Neuromuscular Blockade Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Neuromuscular Blockade Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Neuromuscular Blockade Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Neuromuscular Blockade Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Neuromuscular Blockade Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Neuromuscular Blockade Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Neuromuscular Blockade Drugs Sales in Value by Region (2024-2029)
8 Latin America Neuromuscular Blockade Drugs by Country
8.1 Latin America Neuromuscular Blockade Drugs Historic Market Size by Country
8.1.1 Latin America Neuromuscular Blockade Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Neuromuscular Blockade Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Neuromuscular Blockade Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Neuromuscular Blockade Drugs Forecasted Market Size by Country
8.2.1 Latin America Neuromuscular Blockade Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Neuromuscular Blockade Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Neuromuscular Blockade Drugs by Country
9.1 Middle East and Africa Neuromuscular Blockade Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Neuromuscular Blockade Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Neuromuscular Blockade Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Neuromuscular Blockade Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Neuromuscular Blockade Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Neuromuscular Blockade Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Neuromuscular Blockade Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 F. Hoffmann-La Roche Ltd Company Information
10.1.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
10.1.3 F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Products Offered
10.1.5 F. Hoffmann-La Roche Ltd Recent Development
10.2 Mylan N.V
10.2.1 Mylan N.V Company Information
10.2.2 Mylan N.V Introduction and Business Overview
10.2.3 Mylan N.V Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Mylan N.V Neuromuscular Blockade Drugs Products Offered
10.2.5 Mylan N.V Recent Development
10.3 Teva Pharmaceutical Industries Ltd
10.3.1 Teva Pharmaceutical Industries Ltd Company Information
10.3.2 Teva Pharmaceutical Industries Ltd Introduction and Business Overview
10.3.3 Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Products Offered
10.3.5 Teva Pharmaceutical Industries Ltd Recent Development
10.4 Sanofi
10.4.1 Sanofi Company Information
10.4.2 Sanofi Introduction and Business Overview
10.4.3 Sanofi Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Sanofi Neuromuscular Blockade Drugs Products Offered
10.4.5 Sanofi Recent Development
10.5 Pfizer Inc
10.5.1 Pfizer Inc Company Information
10.5.2 Pfizer Inc Introduction and Business Overview
10.5.3 Pfizer Inc Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Pfizer Inc Neuromuscular Blockade Drugs Products Offered
10.5.5 Pfizer Inc Recent Development
10.6 GSK plc
10.6.1 GSK plc Company Information
10.6.2 GSK plc Introduction and Business Overview
10.6.3 GSK plc Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 GSK plc Neuromuscular Blockade Drugs Products Offered
10.6.5 GSK plc Recent Development
10.7 Novartis AG
10.7.1 Novartis AG Company Information
10.7.2 Novartis AG Introduction and Business Overview
10.7.3 Novartis AG Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Novartis AG Neuromuscular Blockade Drugs Products Offered
10.7.5 Novartis AG Recent Development
10.8 AstraZeneca
10.8.1 AstraZeneca Company Information
10.8.2 AstraZeneca Introduction and Business Overview
10.8.3 AstraZeneca Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 AstraZeneca Neuromuscular Blockade Drugs Products Offered
10.8.5 AstraZeneca Recent Development
10.9 Johnson & Johnson Private Limited
10.9.1 Johnson & Johnson Private Limited Company Information
10.9.2 Johnson & Johnson Private Limited Introduction and Business Overview
10.9.3 Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Products Offered
10.9.5 Johnson & Johnson Private Limited Recent Development
10.10 Sun Pharmaceutical Industries Ltd
10.10.1 Sun Pharmaceutical Industries Ltd Company Information
10.10.2 Sun Pharmaceutical Industries Ltd Introduction and Business Overview
10.10.3 Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Products Offered
10.10.5 Sun Pharmaceutical Industries Ltd Recent Development
10.11 Merck & Co., Inc
10.11.1 Merck & Co., Inc Company Information
10.11.2 Merck & Co., Inc Introduction and Business Overview
10.11.3 Merck & Co., Inc Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Merck & Co., Inc Neuromuscular Blockade Drugs Products Offered
10.11.5 Merck & Co., Inc Recent Development
10.12 Lilly
10.12.1 Lilly Company Information
10.12.2 Lilly Introduction and Business Overview
10.12.3 Lilly Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Lilly Neuromuscular Blockade Drugs Products Offered
10.12.5 Lilly Recent Development
10.13 Amgen Inc
10.13.1 Amgen Inc Company Information
10.13.2 Amgen Inc Introduction and Business Overview
10.13.3 Amgen Inc Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Amgen Inc Neuromuscular Blockade Drugs Products Offered
10.13.5 Amgen Inc Recent Development
10.14 Actelion Pharmaceuticals Ltd
10.14.1 Actelion Pharmaceuticals Ltd Company Information
10.14.2 Actelion Pharmaceuticals Ltd Introduction and Business Overview
10.14.3 Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Products Offered
10.14.5 Actelion Pharmaceuticals Ltd Recent Development
10.15 Endo International plc
10.15.1 Endo International plc Company Information
10.15.2 Endo International plc Introduction and Business Overview
10.15.3 Endo International plc Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Endo International plc Neuromuscular Blockade Drugs Products Offered
10.15.5 Endo International plc Recent Development
10.16 Intas Pharmaceuticals Ltd
10.16.1 Intas Pharmaceuticals Ltd Company Information
10.16.2 Intas Pharmaceuticals Ltd Introduction and Business Overview
10.16.3 Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Products Offered
10.16.5 Intas Pharmaceuticals Ltd Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Neuromuscular Blockade Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Neuromuscular Blockade Drugs Industrial Chain Analysis
11.4 Neuromuscular Blockade Drugs Market Dynamics
11.4.1 Neuromuscular Blockade Drugs Industry Trends
11.4.2 Neuromuscular Blockade Drugs Market Drivers
11.4.3 Neuromuscular Blockade Drugs Market Challenges
11.4.4 Neuromuscular Blockade Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Neuromuscular Blockade Drugs Distributors
12.3 Neuromuscular Blockade Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Depolarizing
Table 2. Major Company of Non-Depolarizing
Table 3. Global Neuromuscular Blockade Drugs Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 4. Global Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (K Units)
Table 5. Global Neuromuscular Blockade Drugs Sales Market Share in Volume by Type (2018-2024)
Table 6. Global Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (US& Million)
Table 7. Global Neuromuscular Blockade Drugs Market Share in Value by Type (2018-2024)
Table 8. Global Neuromuscular Blockade Drugs Price by Type (2018-2024) & (US$/Unit)
Table 9. Global Neuromuscular Blockade Drugs Sales by Type (2024-2029) & (K Units)
Table 10. Global Neuromuscular Blockade Drugs Sales Market Share in Volume by Type (2024-2029)
Table 11. Global Neuromuscular Blockade Drugs Sales by Type (2024-2029) & (US$ Million)
Table 12. Global Neuromuscular Blockade Drugs Sales Market Share in Value by Type (2024-2029)
Table 13. Global Neuromuscular Blockade Drugs Price by Type (2024-2029) & (US$/Unit)
Table 14. North America Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (K Units)
Table 15. North America Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (US$ Million)
Table 16. Europe Neuromuscular Blockade Drugs Sales (K Units) by Type (2018-2024)
Table 17. Europe Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (US$ Million)
Table 18. Asia-Pacific Neuromuscular Blockade Drugs Sales (K Units) by Type (2018-2024)
Table 19. Asia-Pacific Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (US$ Million)
Table 20. Latin America Neuromuscular Blockade Drugs Sales (K Units) by Type (2018-2024)
Table 21. Latin America Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (US$ Million)
Table 22. Middle East and Africa Neuromuscular Blockade Drugs Sales (K Units) by Type (2018-2024)
Table 23. Middle East and Africa Neuromuscular Blockade Drugs Sales by Type (2018-2024) & (US$ Million)
Table 24. Global Neuromuscular Blockade Drugs Sales by Company (2018-2024) & (K Units)
Table 25. Global Neuromuscular Blockade Drugs Sales Share by Company (2018-2024)
Table 26. Global Neuromuscular Blockade Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 27. Global Neuromuscular Blockade Drugs Revenue Share by Company (2018-2024)
Table 28. Global Market Neuromuscular Blockade Drugs Price by Company (2018-2024) & (US$/Unit)
Table 29. Global Neuromuscular Blockade Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global Neuromuscular Blockade Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuromuscular Blockade Drugs as of 2022)
Table 32. Date of Key Manufacturers Enter into Neuromuscular Blockade Drugs Market
Table 33. Key Manufacturers Neuromuscular Blockade Drugs Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Neuromuscular Blockade Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 36. Global Neuromuscular Blockade Drugs Sales by Region (2018-2024) & (K Units)
Table 37. Global Neuromuscular Blockade Drugs Sales Market Share in Volume by Region (2018-2024)
Table 38. Global Neuromuscular Blockade Drugs Sales by Region (2018-2024) & (US$ Million)
Table 39. Global Neuromuscular Blockade Drugs Sales Market Share in Value by Region (2018-2024)
Table 40. Global Neuromuscular Blockade Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 41. Global Neuromuscular Blockade Drugs Sales by Region (2024-2029) & (K Units)
Table 42. Global Neuromuscular Blockade Drugs Sales Market Share in Volume by Region (2024-2029)
Table 43. Global Neuromuscular Blockade Drugs Sales by Region (2024-2029) & (US$ Million)
Table 44. Global Neuromuscular Blockade Drugs Sales Market Share in Value by Region (2024-2029)
Table 45. Global Neuromuscular Blockade Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 46. Global Neuromuscular Blockade Drugs Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 47. Global Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (K Units)
Table 48. Global Neuromuscular Blockade Drugs Sales Market Share in Volume by Application (2018-2024)
Table 49. Global Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (US$ Million)
Table 50. Global Neuromuscular Blockade Drugs Sales Market Share in Value by Application (2018-2024)
Table 51. Global Neuromuscular Blockade Drugs Price by Application (2018-2024) & (US$/Unit)
Table 52. Global Neuromuscular Blockade Drugs Sales by Application (2024-2029) & (K Units)
Table 53. Global Neuromuscular Blockade Drugs Sales Market Share in Volume by Application (2024-2029)
Table 54. Global Neuromuscular Blockade Drugs Sales by Application (2024-2029) & (US$ Million)
Table 55. Global Neuromuscular Blockade Drugs Sales Market Share in Value by Application (2024-2029)
Table 56. Global Neuromuscular Blockade Drugs Price by Application (2024-2029) & (US$/Unit)
Table 57. North America Neuromuscular Blockade Drugs Sales by Application (2018-2024) (K Units)
Table 58. North America Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (US$ Million)
Table 59. Europe Neuromuscular Blockade Drugs Sales by Application (2018-2024) (K Units)
Table 60. Europe Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (US$ Million)
Table 61. Asia-Pacific Neuromuscular Blockade Drugs Sales by Application (2018-2024) (K Units)
Table 62. Asia-Pacific Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (US$ Million)
Table 63. Latin America Neuromuscular Blockade Drugs Sales by Application (2018-2024) (K Units)
Table 64. Latin America Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Neuromuscular Blockade Drugs Sales by Application (2018-2024) (K Units)
Table 66. Middle East and Africa Neuromuscular Blockade Drugs Sales by Application (2018-2024) & (US$ Million)
Table 67. North America Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (K Units)
Table 68. North America Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2018-2024)
Table 69. North America Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (US$ Million)
Table 70. North America Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2018-2024)
Table 71. North America Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (K Units)
Table 72. North America Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2024-2029)
Table 73. North America Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (US$ Million)
Table 74. North America Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2024-2029)
Table 75. Europe Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (K Units)
Table 76. Europe Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2018-2024)
Table 77. Europe Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (US$ Million)
Table 78. Europe Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2018-2024)
Table 79. Europe Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (K Units)
Table 80. Europe Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2024-2029)
Table 81. Europe Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (US$ Million)
Table 82. Europe Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2024-2029)
Table 83. Asia-Pacific Neuromuscular Blockade Drugs Sales by Region (2018-2024) & (K Units)
Table 84. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Volume by Region (2018-2024)
Table 85. Asia-Pacific Neuromuscular Blockade Drugs Sales by Region (2018-2024) & (US$ Million)
Table 86. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Value by Region (2018-2024)
Table 87. Asia-Pacific Neuromuscular Blockade Drugs Sales by Region (2024-2029) & (K Units)
Table 88. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Volume by Region (2024-2029)
Table 89. Asia-Pacific Neuromuscular Blockade Drugs Sales by Region (2024-2029) & (US$ Million)
Table 90. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Value by Region (2024-2029)
Table 91. Latin America Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (K Units)
Table 92. Latin America Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2018-2024)
Table 93. Latin America Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (US$ Million)
Table 94. Latin America Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2018-2024)
Table 95. Latin America Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (K Units)
Table 96. Latin America Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2024-2029)
Table 97. Latin America Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (US$ Million)
Table 98. Latin America Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2024-2029)
Table 99. Middle East and Africa Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (K Units)
Table 100. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2018-2024)
Table 101. Middle East and Africa Neuromuscular Blockade Drugs Sales by Country (2018-2024) & (US$ Million)
Table 102. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2018-2024)
Table 103. Middle East and Africa Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (K Units)
Table 104. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Volume by Country (2024-2029)
Table 105. Middle East and Africa Neuromuscular Blockade Drugs Sales by Country (2024-2029) & (US$ Million)
Table 106. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Value by Country (2024-2029)
Table 107. F. Hoffmann-La Roche Ltd Company Information
Table 108. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 109. F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Product
Table 111. F. Hoffmann-La Roche Ltd Recent Development
Table 112. Mylan N.V Company Information
Table 113. Mylan N.V Introduction and Business Overview
Table 114. Mylan N.V Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Mylan N.V Neuromuscular Blockade Drugs Product
Table 116. Mylan N.V Recent Development
Table 117. Teva Pharmaceutical Industries Ltd Company Information
Table 118. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
Table 119. Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product
Table 121. Teva Pharmaceutical Industries Ltd Recent Development
Table 122. Sanofi Company Information
Table 123. Sanofi Introduction and Business Overview
Table 124. Sanofi Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Sanofi Neuromuscular Blockade Drugs Product
Table 126. Sanofi Recent Development
Table 127. Pfizer Inc Company Information
Table 128. Pfizer Inc Introduction and Business Overview
Table 129. Pfizer Inc Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Pfizer Inc Neuromuscular Blockade Drugs Product
Table 131. Pfizer Inc Recent Development
Table 132. GSK plc Company Information
Table 133. GSK plc Introduction and Business Overview
Table 134. GSK plc Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. GSK plc Neuromuscular Blockade Drugs Product
Table 136. GSK plc Recent Development
Table 137. Novartis AG Company Information
Table 138. Novartis AG Introduction and Business Overview
Table 139. Novartis AG Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Novartis AG Neuromuscular Blockade Drugs Product
Table 141. Novartis AG Recent Development
Table 142. AstraZeneca Company Information
Table 143. AstraZeneca Introduction and Business Overview
Table 144. AstraZeneca Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. AstraZeneca Neuromuscular Blockade Drugs Product
Table 146. AstraZeneca Recent Development
Table 147. Johnson & Johnson Private Limited Company Information
Table 148. Johnson & Johnson Private Limited Introduction and Business Overview
Table 149. Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Product
Table 151. Johnson & Johnson Private Limited Recent Development
Table 152. Sun Pharmaceutical Industries Ltd Company Information
Table 153. Sun Pharmaceutical Industries Ltd Introduction and Business Overview
Table 154. Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product
Table 156. Sun Pharmaceutical Industries Ltd Recent Development
Table 157. Merck & Co., Inc Company Information
Table 158. Merck & Co., Inc Introduction and Business Overview
Table 159. Merck & Co., Inc Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Merck & Co., Inc Neuromuscular Blockade Drugs Product
Table 161. Merck & Co., Inc Recent Development
Table 162. Lilly Company Information
Table 163. Lilly Introduction and Business Overview
Table 164. Lilly Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Lilly Neuromuscular Blockade Drugs Product
Table 166. Lilly Recent Development
Table 167. Amgen Inc Company Information
Table 168. Amgen Inc Introduction and Business Overview
Table 169. Amgen Inc Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Amgen Inc Neuromuscular Blockade Drugs Product
Table 171. Amgen Inc Recent Development
Table 172. Actelion Pharmaceuticals Ltd Company Information
Table 173. Actelion Pharmaceuticals Ltd Introduction and Business Overview
Table 174. Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product
Table 176. Actelion Pharmaceuticals Ltd Recent Development
Table 177. Endo International plc Company Information
Table 178. Endo International plc Introduction and Business Overview
Table 179. Endo International plc Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 180. Endo International plc Neuromuscular Blockade Drugs Product
Table 181. Endo International plc Recent Development
Table 182. Intas Pharmaceuticals Ltd Company Information
Table 183. Intas Pharmaceuticals Ltd Introduction and Business Overview
Table 184. Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 185. Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product
Table 186. Intas Pharmaceuticals Ltd Recent Development
Table 187. Key Raw Materials Lists
Table 188. Raw Materials Key Suppliers Lists
Table 189. Neuromuscular Blockade Drugs Market Trends
Table 190. Neuromuscular Blockade Drugs Market Drivers
Table 191. Neuromuscular Blockade Drugs Market Challenges
Table 192. Neuromuscular Blockade Drugs Market Restraints
Table 193. Neuromuscular Blockade Drugs Distributors List
Table 194. Neuromuscular Blockade Drugs Downstream Customers
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuromuscular Blockade Drugs Product Picture
Figure 2. Global Neuromuscular Blockade Drugs Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Neuromuscular Blockade Drugs Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Neuromuscular Blockade Drugs Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Depolarizing
Figure 6. Global Depolarizing Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Non-Depolarizing
Figure 8. Global Non-Depolarizing Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Global Neuromuscular Blockade Drugs Sales by Type (2018-2029) & (US$ Million)
Figure 10. Global Neuromuscular Blockade Drugs Sales Market Share by Type in 2022 & 2029
Figure 11. North America Neuromuscular Blockade Drugs Sales Market Share in Volume by Type in 2022
Figure 12. North America Neuromuscular Blockade Drugs Sales Market Share in Value by Type in 2022
Figure 13. Europe Neuromuscular Blockade Drugs Sales Market Share in Volume by Type in 2022
Figure 14. Europe Neuromuscular Blockade Drugs Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Value by Type in 2022
Figure 17. Latin America Neuromuscular Blockade Drugs Sales Market Share in Volume by Type in 2022
Figure 18. Latin America Neuromuscular Blockade Drugs Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Neuromuscular Blockade Drugs Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Neuromuscular Blockade Drugs Revenue in 2022
Figure 23. Neuromuscular Blockade Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 24. Product Picture of Hospitals
Figure 25. Global Hospitals Sales YoY Growth (2018-2029) & (K Units)
Figure 26. Product Picture of Specialty Clinics
Figure 27. Global Specialty Clinics Sales YoY Growth (2018-2029) & (K Units)
Figure 28. Product Picture of Other
Figure 29. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Global Neuromuscular Blockade Drugs Sales by Application (2018-2029) & (US$ Million)
Figure 31. Global Neuromuscular Blockade Drugs Sales Market Share by Application in 2022 & 2029
Figure 32. North America Neuromuscular Blockade Drugs Sales Market Share in Volume by Application in 2022
Figure 33. North America Neuromuscular Blockade Drugs Sales Market Share in Value by Application in 2022
Figure 34. Europe Neuromuscular Blockade Drugs Sales Market Share in Volume by Application in 2022
Figure 35. Europe Neuromuscular Blockade Drugs Sales Market Share in Value by Application in 2022
Figure 36. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Volume by Application in 2022
Figure 37. Asia-Pacific Neuromuscular Blockade Drugs Sales Market Share in Value by Application in 2022
Figure 38. Latin America Neuromuscular Blockade Drugs Sales Market Share in Volume by Application in 2022
Figure 39. Latin America Neuromuscular Blockade Drugs Sales Market Share in Value by Application in 2022
Figure 40. Middle East and Africa Neuromuscular Blockade Drugs Sales Market Share in Value by Application in 2022
Figure 41. Key Raw Materials Price
Figure 42. Neuromuscular Blockade Drugs Manufacturing Cost Structure
Figure 43. Neuromuscular Blockade Drugs Industrial Chain Analysis
Figure 44. Channels of Distribution
Figure 45. Distributors Profiles
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed